This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

SAVE UP TO $700 IF YOU BOOK BEFORE JULY 17 2021

  • 00
    DAYS
  • 00
    HRS
  • 00
    MINS
  • 00
    SECS
Delivered as a Hybrid Event from December 12 - 16, 2021
Live In-Person Experience Delivered December 12 - 16 2021Marriott Marquis San Diego

ANTIBODY ENGINEERING & THERAPEUTICS: THE 2021 ADVISORY BOARD

Antibody Engineering & Therapeutics US 2021 has been created in conjunction with leading experts and scientists from across the Antibody community.

Take a look at the advisory board to see who played a part in this year's schedule.

The 2021 Advisory Board


  • Gregory Adams, Ph.D., Chief Scientific Officer, Elucida Oncology
  • Andrew Bradbury, M.D., Ph.D., Chief Scientific Officer, Specifica
  • Dennis R. Burton, Ph.D., Professor, Department of Immunology and Microbiology, The Scripps Research Institute
  • Paul J. Carter, Ph.D., Genentech Fellow, Department of Antibody Engineering, Genentech, Inc.
  • Kerry A. Chester, Ph.D., Professor of Molecular Medicine, UCL Cancer Institute, University College London, United Kingdom
  • Jennifer Cochran, Ph.D., Professor and Department Chair of Bioengineering, Stanford University
  • Mitchell Ho, Ph.D., Senior Investigator, Laboratory of Molecular Biology, NIH NCI
  • James Larrick, M.D., Ph.D., Managing Director and Chief Medical Officer, Panorama Research Institute and Velocity Pharmaceutical Development
  • Paul W.H.I. Parren, Ph.D., Professor, Department of Immunohematology and Blood Transfusion, Leiden University Medical Center and EVP and Head of R&D, Lava Therapeutics, The Netherlands
  • Andreas Plückthun, Ph.D., Professor and Director, Department of Biochemistry, University of Zürich, Switzerland
  • Nina Luning Prak, M.D., Ph.D., Professor of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania
  • Sai Reddy, Ph.D., Associate Professor, Department of Biosystems Science and Engineering, ETH Zurich/Swiss Federal Institute of Technology, Switzerland
  • Janice M. Reichert, Ph.D., Executive Director, The Antibody Society; Editor-in-Chief, mAbs; Managing Director, Reichert Biotechnology Consulting LLC
  • Janine Schuurman, Ph.D., Vice President, Research, Genmab, The Netherlands
  • Sally Ward, Ph.D., Professor and Director, University of Southampton, United Kingdom
  • K. Dane Wittrup, Ph.D., C.P. Dubbs Professor of Chemical Engineering and Biological Engineering, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology